Holen Sie sich die Stockscreener-App
3.58
4.68%
0.16
Handel nachbörslich:
3.61
0.03
+0.84%
Schlusskurs vom Vortag:
$3.42
Offen:
$3.44
24-Stunden-Volumen:
1.78M
Relative Volume:
1.38
Marktkapitalisierung:
$618.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-10.85
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
+9.48%
1M Leistung:
+39.30%
6M Leistung:
+49.79%
1J Leistung:
-18.82%
1-Tages-Spanne:
$3.39
$3.635
1-Wochen-Bereich:
$3.1941
$3.635
52-Wochen-Spanne:
$1.89
$4.70
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Vergleichen Sie SVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
3.58 | 572.09M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
Sector ETF performance correlation with Savara Inc.Weekly Gains Report & Community Trade Idea Sharing - Newser
What high frequency data says about Savara Inc.GDP Growth & AI Forecast Swing Trade Picks - Newser
Will Savara Inc. continue its uptrendWeekly Investment Recap & Smart Investment Allocation Tips - Newser
Savara’s Expanding aPAP Market and Strategic Moves Justify Buy Rating with Increased Price Target - TipRanks
Will Savara Inc. stock go up soonTrade Volume Summary & Short-Term High Return Ideas - Newser
Savara Inc. stock chart pattern explained2025 Trade Ideas & Weekly Hot Stock Watchlists - Newser
Market reaction to Savara Inc.’s recent newsQuarterly Trade Summary & Daily Price Action Insights - Newser
Comparing Savara Inc. in custom built stock radarsJuly 2025 Movers & Safe Capital Growth Tips - Newser
Is Savara Inc. stock poised for growth2025 EndofYear Setup & Technical Confirmation Alerts - Newser
How institutional ownership impacts Savara Inc. stockEarnings Growth Report & Free Expert Verified Stock Movement Alerts - Newser
Savara Highlights MOLBREEVI Development in New Presentation - TipRanks
Regression analysis insights on Savara Inc. performance2025 Key Highlights & Stepwise Swing Trade Plans - Newser
Will a bounce in Savara Inc. offer an exitJuly 2025 Breakouts & Real-Time Market Trend Scan - Newser
Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Numbe - PharmiWeb.com
Trend analysis for Savara Inc. this weekJuly 2025 Market Mood & Stepwise Swing Trade Plans - Newser
Does Savara Inc. stock reflect fundamentals2025 Market WrapUp & Weekly Top Gainers Trade List - khodrobank.com
50% Jump in Rare Lung Disease Patients: Savara Finds 5,500 U.S. Cases Ahead of FDA Drug Review - Stock Titan
What candlestick patterns are forming on Savara Inc.Watch List & Momentum Based Trading Ideas - Newser
Savara’s SWOT analysis: molbreevi’s potential reshapes rare respiratory stock outlook - Investing.com
Earnings Chart Overlay Points to Savara Inc. Upside getLinesFromResByArray error: size == 0 - kangso.co.kr
Will Savara Inc. announce a stock split2025 Technical Overview & Precise Swing Trade Alerts - khodrobank.com
Quant Funds Rotate Into Savara Inc. StockJuly 2025 Summary & Verified High Yield Trade Plans - beatles.ru
Earnings visualization tools for Savara Inc.Weekly Profit Report & Daily Volume Surge Trade Alerts - Newser
Published on: 2025-08-31 18:39:16 - Newser
Long term hold vs stop loss in Savara Inc.2025 Technical Patterns & Free Expert Approved Momentum Trade Ideas - Newser
Published on: 2025-09-01 23:59:49 - Newser
Best data tools to analyze Savara Inc. stockRisk Management & Weekly High Conviction Ideas - Newser
What technical models suggest about Savara Inc.’s comebackShare Buyback & AI Enhanced Market Trend Forecasts - Newser
Why Savara Inc. stock attracts strong analyst attention2025 Technical Patterns & Long-Term Safe Investment Plans - Newser
Using flow based indicators on Savara Inc.2025 Macro Impact & Reliable Volume Spike Trade Alerts - Newser
Order flow analysis tools used on Savara Inc.July 2025 Institutional & Stepwise Swing Trade Plans - Newser
Savara Inc. Building a Base Near Support getLinesFromResByArray error: size == 0 - kangso.co.kr
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Savara Inc-Aktie (SVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McCracken Joseph S | Director |
May 29 '25 |
Buy |
2.08 |
10,000 |
20,825 |
260,837 |
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):